OTC · Healthcare
Aspira Women's Health Inc. (AWHL)
As-reported financials and recent SEC filings for Aspira Women's Health Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$9.2M
Net income
$-12.8M
Net margin
-138.7%
Diluted EPS
$-0.37
ROE
184.4%
P/E (TTM)
—
Market cap
—
Debt / equity
-0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.2M | $9.2M | $87.0M | $8.2M | $6.8M |
| Gross profit | $5.9M | $5.5M | — | $4.3M | $3.1M |
| Operating income | $-7.9M | $-16.3M | $-18.9M | $-31.1M | $-32.6M |
| Net income | $-12.8M | $-13.1M | $-16.7M | $-29.9M | $-31.7M |
| Diluted EPS | $-0.37 | $-0.47 | $-0.91 | $-1.93 | $-2.13 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
D2026-06-22
View on EDGAR →8-K2026-06-22
View on EDGAR →8-K2026-06-17
View on EDGAR →SCHEDULE 13D/A2026-06-11
View on EDGAR →42026-06-09
View on EDGAR →8-K2026-06-09
View on EDGAR →42026-05-29
View on EDGAR →4/A2026-05-29
View on EDGAR →Largest Healthcare peers
Go deeper on AWHL
Search Aspira Women's Health Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.